Our Work in Rheumatology
Targeted biologics, the recent emergence of innovative new oral therapies, and the arrival of biosimilars will continue to fuel monumental shifts in the way patients with auto-immune disorders are managed. More than ever, for both existing brands & pipeline products, future success will require a deep understanding of this complex and rapidly evolving landscape.
Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Systemic Sclerosis, Systemic Lupus Erythematosus, Vasculitis (GCA, PMR, ANCA), Gout
Board of Advisors
The primary objectives of advocacy groups are to educate, advocate, collaborate, and improve the efficiency of services for individuals with rheumatology related diseases and those who are close to them.
In Rheumatoid Arthritis, TNF Cycling Continues to Be Highly Prevalent, Though Alternate Mechanism Agents Are Capturing a Greater Percentage of the Switching Population Compared to the Prior Year – December 4, 2018
More Rheumatologists are Using Pfizer’s Xeljanz in Psoriatic Arthritis Patients, Outpacing the Impressive Growth Displayed by Eli Lilly’s Taltz in the Previous Quarter – October 8, 2018
Ankylosing Spondylitis Market Largely Dominated by TNF-Inhibitors, Though Novartis’ Cosentyx Enjoyed Significant Year Over Year Gains and a Growing Percent of Rheumatologists Report Off-Label Use of Pfizer’s Xeljanz – September 6, 2018
ACR/ARHP Annual Meeting 2018